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Tauopathies are neurodegenerative diseases characterized by intraneuronal inclusions of hyperphosphorylated tau protein and abnor-
mal expression of brain-derived neurotrophic factor (BDNF), a key modulator of neuronal survival and function. The severity of both
these pathological hallmarks correlate with the degree of cognitive impairment in patients. However, how tau pathology specifically
modifies BDNF signaling and affects neuronal functionduring early prodromal stages of tauopathy remains unclear.Here,we report that
the mild tauopathy developing in retinal ganglion cells (RGCs) of the P301S tau transgenic (P301S) mouse induces functional retinal
changes by disrupting BDNF signaling via the TrkB receptor. In adult P301S mice, the physiological visual response of RGCs to pattern
light stimuli and retinal acuity decline significantly. As a consequence, the activity-dependent secretion of BDNF in the vitreous is
impaired in P301S mice. Further, in P301S retinas, TrkB receptors are selectively upregulated, but uncoupled from downstream extra-
cellular signal-regulatedkinase (ERK)1/2 signaling.Wealso showthat the impairmentofTrkBsignaling is triggeredby taupathologyand
mediates the tau-induced dysfunction of visual response. Overall our results identify a neurotrophin-mediatedmechanism bywhich tau
inducesneuronal dysfunctionduringprodromal stages of tauopathy anddefine tau-drivenpathophysiological changes of potential value
to support early diagnosis and informed therapeutic decisions.
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Introduction
Intraneuronal inclusions made of filaments of hyperphosphory-
lated microtubule-associated tau protein are neuropathological
hallmarks of a subset of neurodegenerative diseases termed
tauopathies, which include Alzheimer’s disease (AD), cortico-
basal degeneration, progressive parasupranuclear palsy, and
frontotemporal dementia. In AD, levels of tau species, including
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Significance Statement
This work highlights the potential molecular mechanisms by which initial tauopathy induces neuronal dysfunction. Combining
clinically used electrophysiological techniques (i.e., electroretinography) and molecular analyses, this work shows that in a
relevant model of early tauopathy, the retina of the P301S mutant human tau transgenic mouse, mild tau pathology results in
functional changes of neuronal activity, likely due to selective impairment of brain-derived neurotrophic factor signaling via its
receptor, TrkB. These findings may have important translational implications for early diagnosis in a subset of Alzheimer’s
disease patients with early visual symptoms and emphasize the need to clarify the pathophysiological changes associated with
distinct tauopathy stages to support informed therapeutic decisions and guide drug discovery.
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total tau and phospho-tau, are altered in the CSF of subjects at
risk for AD several years before putative onset of clinical symp-
toms (Bateman et al., 2012) and the development of tauopathy
strongly correlates with the severity of cognitive impairment in
patients (Arriagada et al., 1992; Go´mez-Isla et al., 1997). How-
ever, the mechanisms by which tau affects neuronal physiology
during prodromal stages of tauopathy remain unclear.
The P301S mutant human tau transgenic (P301S) mouse (Al-
len et al., 2002), a model of tauopathy, develops tau inclusions
throughout the CNS, leading to neuronal loss in the spinal cord
(Allen et al., 2002) and cortex (Hampton et al., 2010) and to
behavioral deficits (Scattoni et al., 2010). The inner retina of
P301S mice also develops mild tau pathology (Gasparini et al.,
2011), resembling initial pathological stages. In P301S retinas,
transgenic mutant tau is expressed only in retinal ganglion cells
(RGCs); its hyperphosphorylated form accumulates in the nerve-
fiber and RGC layers of the inner retina and, in a few RGCs, forms
insoluble tau filament aggregates (Gasparini et al., 2011). Al-
though none of these changes alters the overall anatomy of the
retina— both inner and outer— or causes loss of neurons, P301S
retinal explants in vitro display growing abnormalities. In partic-
ular, in retinal explants cultured from adult P301S mice, RGC
axonal outgrowth does not respond to neurotrophic stimuli, sug-
gesting that tau pathology alters neurotrophin signaling (Gas-
parini et al., 2011).
Among the neurotrophins, brain-derived neurotrophic factor
(BDNF) plays a key role in promoting neuronal survival, synaptic
plasticity, and memory consolidation (Lu, 2003; Binder and
Scharfman, 2004; Gezen-Ak et al., 2013). Dysregulation of its
levels and signaling has been linked to neurodegeneration. BDNF
mRNA and protein are decreased in the blood (Pla´teník et al.,
2014) and brain of patients with AD (Phillips et al., 1991; Connor
et al., 1997; Ferrer et al., 1999; Hock et al., 2000; Holsinger et al.,
2000; Peng et al., 2005) and the extent of BDNF reduction corre-
lates with the degree of cognitive impairment (Peng et al., 2005).
In transgenic mouse AD models overexpressing mutant human
-amyloid precursor protein, administering BDNF rescues syn-
aptic loss and cognitive dysfunction, implying that the loss of
BDNF contributes to -amyloid-induced pathological changes
(Arancibia et al., 2008; Blurton-Jones et al., 2009; Nagahara et al.,
2009). Decreased BDNF levels have also been found in the pari-
etal cortex of subjects with primary tauopathies, such as cortico-
basal degeneration and Pick’s disease (Belrose et al., 2014). While
a number of studies have investigated the link between BDNF
impairment and -amyloid-induced pathological changes (Song
et al., 2015), how tau pathology specifically modifies BDNF sig-
naling and affects neuronal function during early prodromal
stages of tauopathy remains unclear.
Here, to investigate this central question, we used the P301S
retina as a model of early-stage tauopathy. We find that in the
retina of P301S mice, mild tauopathy causes functional changes
of visual response by disrupting the BDNF signaling via the TrkB
receptor. In 5-month-old P301S mice, the activity of RGCs and
retinal acuity are significantly reduced. Moreover, in the retina of
these mice, BDNF signaling through TrkB receptors is signifi-
cantly impaired both at the level of the ligand and receptor. De-
spite normal retinal expression and synthesis, the amount of
BDNF in the vitreous is significantly reduced, possibly due to
impaired activity-dependent secretion. Further, in P301S retinas,
although TrkB receptors are selectively upregulated, they are un-
coupled from the downstream extracellular signal-regulated ki-
nase (ERK) 1/2 signaling pathway. We also show that both retinal
dysfunction and TrkB upregulation are triggered by tau pathol-
ogy and that tau-induced BDNF signaling impairment contrib-
utes to the reduced visual response.
Materials andMethods
Transgenic mice. Homozygous P301S transgenic mice (Allen et al., 2002)
and age-matched C57BL/6 wild-type (WT) mice of either sex were used.
Animal health and comfort were veterinary controlled. Mice were
housed in filtered cages in a temperature-controlled room with a 12:12 h
dark/light cycle with ad libitum access to water and food. All animal
experiments were performed in full compliance with the European Com-
munity Council directive 86/609/EEC and the revised directive 2010/63/
EU, and were approved by the Italian Ministry of Health and by the
Istituto Italiano di Tecnologia Animal Facility Committee.
Antibodies and reagents. The following primary antibodies were used:
monoclonal antibodies against BDNF (clone 35928.11; Sigma-Aldrich),
I-tubulin, actin (Sigma-Aldrich), p44/42 MAPK (3A7), p44/42 MAPK
(Thr202/Tyr204; Cell Signaling Technology), tau (Tau5; Calbiochem),
human tau (HT7; ThermoFisher Scientific), phospho-tau (AT8; Auto-
gen Bioclear), phospho-Y18 tau (9G3; Me´diMabs), PHF-1 and MC1
phospho-tau (kind gift from Dr. P. Davies, Albert Einstein College of
Medicine, New York, NY); Trk (clone B-3), which selectively recognizes
TrkA (Matrone et al., 2011; our unpublished data); fyn (Santa Cruz
Biotechnology); polyclonal antisera against TrkB (clone 07-225, Milli-
pore Biotechnology), which selectively recognizes TrkB (Cazorla et al.,
2011a; our unpublished data); p75NTR (Millipore); phospho-TrkA
(Tyr490)/TrkB (Tyr516); phospho-TrkA (Tyr785)/TrkB (Tyr816);
phospho-p44/42 MAPK (Thr202/Tyr204); phospho(Tyr783)-PLC1,
PLC1 (Cell Signaling Technology), BDNF (Santa Cruz Biotechnology).
For TrkA and TrkB phosphorylation, the PathScan Phospho-TrkA
(Tyr490) Sandwich ELISA and PathScan Phospho-TrkB (Tyr516) Sand-
wich ELISA kits (Cell Signaling Technology) were also used. HRP-
conjugated secondary antibodies were from Bio-Rad Laboratories. For
immunoprecipitation experiments, Western blots were developed using
HRP-conjugated anti-mouse and anti-rabbit light-chain antibodies
(Millipore). All reagents were from Sigma-Aldrich unless otherwise spec-
ified. Stock solution of tetrodotoxin (TTX; Tocris Bioscience) was pre-
pared in saline at 1 mM and diluted to 5M. ANA12 (Sigma-Aldrich) was
dissolved at 20 mg/ml in DMSO and resuspended in saline by sonication
with a final DMSO concentration of 0.5%. The stock solution of the ERK
inhibitor PD0325901 (Sigma-Aldrich) was 5 M in DMSO.
Pattern electroretinogram. Mice were anesthetized with intraperitoneal
injections of 2 g/kg urethane, gently restrained using a mouth bite bar
and nose holder that allowed unobstructed vision, and kept at a constant
body temperature of 37°C using a feedback-controlled heating pad. Un-
der these conditions, the eyes of mice were naturally wide open and in a
stable position, with pupils pointing laterally and upward. The silver
recording electrode was gently placed on the corneal surface encircling
the undilated pupil without interfering with vision. The ground electrode
was a small stainless steel needle inserted in the skin of the back of the
head. Visual stimuli were displayed on a 17 inch monitor (Biomedica
Mangoni) whose center was aligned with the projection of the pupil and
presented at a distance of 20 cm from the mouse’s eye. Pattern stimuli
consisted of horizontal, square grating bars of constant luminance, con-
trast, and spatial and temporal frequencies. The standard grating contrast
was 90%, with a 1 Hz reversal rate, and spatial frequency of 0.05 c/deg,
which maximize pattern electroretinogram (ERG) amplitude in the
mouse (Porciatti, 2007; Porciatti et al., 2007).
In selected experiments, to determine spatial visual acuity, mice were
exposed to pattern stimuli with varying spatial frequencies (0.05– 0.7
c/deg) at constant contrast, luminance, and temporal frequency. Spatial
acuity was calculated as the spatial frequency of the intercept between the
linear regression among data points in a graph, where spatial frequencies
were represented on a logarithmic scale, and the noise level measured
upon presentation of a blank screen.
Flash ERG.Mice were dark adapted for4 h before being anesthetized
under dim red light by intraperitoneal injections of urethane (2 g/kg),
and gently restrained as described above. The pupils were dilated with the
mydriatic agent atropin at 1% in physiological solution. The gold record-
ing electrode (0.25 mm diameter) was gently placed on the corneal sur-
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face encircling the dilated pupil without interfering with vision. The
ground electrode was inserted in the skin of the back of the head. Visual
stimuli consisted of uniform flickers of light of different luminance
(0.001–30 cd s/m 2) presented in scotopic conditions through a Ganzfeld
dome (Biomedica Mangoni).
Western blots.Retinas were lysed by sonication in 150 mM NaCl, 10 mM
Tris, pH 7.4, 1 mM EGTA, 0.5% Triton X-100, and protease and phos-
phatase inhibitors and incubated on ice for 30 min. Samples were spun at
20,800  g for 20 min. The supernatants were collected and protein
concentration was determined using a BCA kit (Pierce). Equal amounts
of protein were separated by electrophoresis on 10 or 7.5% SDS poly-
acrylamide gels (SDS-PAGE) as previously described (Gasparini et al.,
2011). Proteins were transferred overnight at 4°C onto Protran 0.2 NC
nitrocellulose membranes (GE Healthcare). Membranes were blocked
for 1 h at room temperature with 5% milk in phosphate buffer (PBS), pH
7.4, containing 0.05% Tween 20, and incubated overnight at 4°C with the
primary antibody in blocking buffer. Membranes were then rinsed in
Tris-buffered saline, pH 7.4, with 0.05% Tween 20, incubated for 1 h at
room temperature in horseradish peroxidase (HRP)-conjugated second-
ary antibodies (immunopure peroxidase conjugated; ThermoFisher Sci-
entific), and visualized using SuperSignal West Pico Chemiluminescent
Substrate (ThermoFisher Scientific). Chemiluminescent signals were ac-
quired using films (Hyperfilm ECL, GE Healthcare) or an Image Quant
LAS 4000 mini (GE Healthcare). Densitometric analysis was performed
using the National Institutes of Health ImageJ program (Schneider et al.,
2012). Equal loading was verified using MemCode (ThermoFisher Sci-
entific) and levels of I-tubulin or actin. Protein levels were expressed as
a ratio with I-tubulin or actin. Phosphorylated proteins were normal-
ized to the total amount of the respective protein.
RNA isolation and quantitative real-time PCR. Retinas were removed
and snap frozen in dry ice. RNA was isolated using the RNeasy mini kit
(Qiagen) and cDNA was synthesized from 1 g of total RNA using the
First-Strand cDNA Synthesis Kit (Qiagen). Quantitative real-time PCR
was performed using the QuantiFast SYBR Green PCR Kit. (Qiagen) as
previously described (Ferrera et al., 2014). Gene expression data were
normalized to actin and GAPDH using the multiple internal control gene
method with the GeNorm algorithm available in the qBasePlus software
(Biogazelle). The following primers were used: TrkB, forward 5-CCACG
GCATGAGCGAGAC-3, reverse 5-CCTAAGCACAACGGACTCCC-3;
BDNF, forward 5-AAGGTCTAGGATGGAGGTGG-3, reverse 5-CTA
AGCAACTTGACACATCATTCC-3; actin, forward 5-AAGTGGTTA
CAGGAAGTCC-3, reverse 5-ATAATTTACACAGAAGCAATGC-3;
GAPDH, forward 5-GAACATCATCCCTGCATCCA-3, reverse 5-CC
AGTGAGCTTCCCGTTCA-3.
Pharmacological treatments.Mice were anesthetized by intraperitoneal
injection of urethane (2 g/kg). Intravitreal injections were performed
under a dissecting microscope with a 30 ga needle attached to a 10l glass
syringe (Hamilton). The needle was positioned posterior to the ora ser-
rata and 0.5l of the solution was slowly (3–5 s) injected into the vitreous
chamber of the eye. A 10 s interval was held before removing the needle.
Mice were killed at different times after injection and retinas were dis-
sected and snap frozen in dry ice. In selected experiments, the following
substances were dissolved in 0.9% NaCl physiological salt solution and
injected intravitreously (0.5 l): 2 g of BDNF, 2 g of nerve growth
factor (NGF), TTX (500 nM final concentration), PD0325901 (20 nM
final concentration), or vehicle (0.4% DMSO in the contralateral eye). In
BDNF stimulation experiments, we used 2 g of BDNF, a dosage based
on the following considerations. Our initial goal was to test the potential
therapeutic use of BDNF for tauopathy. To this purpose, it was impor-
tant to first investigate the function of TrkB signaling. In rodents, the
neuroprotective effects of BDNF on retinal ganglion neurons have been
investigated by several groups using doses ranging from 0.1 to 5 g/eye
(for review, see Khalin et al., 2015), with most studies using 1 g/eye
both in rat and mouse. Specifically, it has been reported that a dose of 2
g/eye of BDNF is neuroprotective and restores retinal function [as-
sessed by pattern ERG (pERG)] in a mouse model of glaucoma (Do-
menici et al., 2014). We thus postulated that 2 g of BDNF (final vitreal
concentration of 0.2 g/l in the mouse) would possibly achieve a
response robust enough to investigate the function of TrkB signaling and
uncover even mild deficits that could affect the efficacy of a potential treat-
ment. To control for nonspecific effects induced by the injection of proteins
or vehicle, bovine serum albumin (BSA) was injected in the contralateral eye
as a control. Initial experiments in WT mice indicated that intravitreal injec-
tion of BSA did not affect the levels of p[Y516]TrkB (p[Y516]TrkB/TrkB ratio,
1.0  0.1), phospho-ERK1 (pERK1/ERK1 ratio, 1.6  0.6), or phospho-
ERK2 (pERK2/ERK2 ratio, 0.7 0.1), which remained similar to those of
untreated retinas (p[Y516]TrkB/TrkB ratio, 1.0 0.1; pERK1/ERK1, 2.0
1.1; pERK2/ERK2, 0.80.3). In selected experiments, TrkB was inhibited by
systemic administration of the TrkB inhibitor ANA12 (Cazorla et al., 2011b)
by intraperitoneal injection at a 1 mg/kg dose. Vehicle (0.5% DMSO in
saline) was injected in control mice.
Intracerebral injections of brain extracts. For intracerebral injection,
brain extracts from P301S (P301SBE) and WT (WTBE) mice were pre-
pared as described previously (Clavaguera et al., 2013). Briefly, brains-
tems from 5-month-old mice were dissected, homogenized in sterile
PBS, and centrifuged at 3000 g at 4°C for 5 min. The supernatant was
aliquoted, snap frozen, and stored at 80°C until use. Levels of tau,
transgenic human tau, and phospho-tau in P301SBE and WTBE were
analyzed by Western blot (see Fig. 6A). P301S transgenic mice 1.5
months old were anesthetized with 2% isoflurane [2-chloro-2-
(difluoromethoxy)-1,1,1-trifluoro-ethane] and placed in a stereotaxic
device. The skull was exposed and kept dry and clean. The bregma was
identified and marked. The designated point of injection was at a depth
of 1 mm from the brain surface, 2.92 mm behind the bregma on the
anteroposterior axis, and 0.5 mm lateral to the midline (see Fig. 6B). A
window was drilled in the scalp above the designated coordinates in the
right and left hemispheres. The lysates (2 l) were then injected using a
Hamilton syringe (Hamilton) with a microinjector (injection rate, 0.5
l/min). After injection, the needle was kept in place for an additional 1
min before gentle withdrawal. The surgical area was cleaned with sterile
saline and the incision sutured. Mice were monitored until recovery from
anesthesia and checked weekly after surgery. For sham-injected mice,
sterile PBS was injected following the same procedure. At 3 months of
age, after recording retinal activity by pERG, mice were killed and brain
tissues were collected for biochemical and immunohistochemical
analyses.
ELISA. The BDNF levels of the vitreous were assayed using the BDNF
Emax ImmunoAssay System (Promega) according to the manufacturer’s
instructions. Briefly, standard 96-well flat-bottom NUNC-Immuno
maxisorp ELISA plates (Costar) were coated overnight at 4°C with the
polyclonal anti-BDNF capturing antibody and blocked with blocking
and sample buffers. Serial dilutions of known amounts of BDNF ranging
from 0 to 500 pg were used for the standard curve. Fifty micrograms of
retinal lysate or 1.5 l of vitreous humor were applied in each well and
incubated 2 h at room temperature with the detecting monoclonal anti-
body against BDNF, followed by an HRP-conjugated anti-human IgG
secondary antibody for 2.5 h at room temperature and colorimetric re-
action with 3,3,5,5-tetramethylbenzidine. After 10 min, the reaction
was terminated by 1 M phosphoric acid and the absorbance at 450 nm was
measured using the Victor 3 V multilabel plate reader (PerkinElmer).
In selected experiments, TrkA and TrkB phosphorylation in the retina
was analyzed using the PathScan Phospho-TrkA (Tyr490) and PathScan
Phospho-TrkB (Tyr516) Sandwich ELISA kits (Cell Signaling Technol-
ogy) according to manufacturer’s instruction. The PathScan TrkA and
PathScan TrkB ELISA kits (Cell Signaling Technology) were also used for
total receptor levels.
Immunohistochemistry and confocalmicroscopy.Retinas from homozy-
gous P301S tau transgenic and C57BL/6 WT mice were analyzed histo-
logically. Briefly, the mice were anesthetized with CO2 and killed by
cervical dislocation. The eyecups were removed and fixed overnight in
4% PFA. Immunohistochemical detection of TrkB and phosphorylated
tau was performed as previously described (Gasparini et al., 2011).
Briefly, 10 m retinal cryostat sections were blocked in 5% normal goat
serum, 1% BSA, and 0.2% Triton PBS for 1 h at room temperature and
incubated overnight at 4°C with primary antibodies. Immunoreactivity
was visualized using secondary antibodies conjugated with Alexa fluoro-
chromes (Invitrogen) for confocal analysis. Nuclei were counterstained
with Hoechst-33342. Confocal microscopy was performed with a Leica
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TCS SP5 (Leica Microsystems) equipped with 63HCX PL APO 1.40 oil
and 40 HCX PL APO 1.25 oil objectives. To quantify the number of
photoreceptor (PR) nuclei in the outer nuclear layer, 3 sections/slide
adjacent to the optic nerve (ON) head were separately counted and av-
eraged as previously described (Rex et al., 2004).
Immunohistochemical analysis of brains from mice injected with
brain extracts or PBS was performed on 30m coronal sections collected
2.80 – 4.60 mm behind bregma. Sections were immunolabeled with AT8
antibody and counterstained with the Congo red analog (E,E)-1-fluoro-
2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (FSB; Sato et al.,
2004) as previously described (Gasparini et al., 2011). Images were col-
lected using an automated Olympus BX51 microscope, equipped with a
MBF Optonic CX9000 camera and 10UPLFLN semi-apo fluorite 10
numerical aperture 0.3 objective and Neurolucida V11 software (MBF
Bioscience) or by confocal microscopy, as described above.
Sarkosyl extraction. Sarkosyl-insoluble tau was extracted from 200 mg
of brain tissue of transgenic and WT age-matched mice as described
previously (Gasparini et al., 2011). Briefly, tissues were homogenized in
10 volumes of cold extraction buffer (10 mM Tris-HCl, pH 7.4, 0.8 M
NaCl, 1 mM EGTA, 10% sucrose) and the homogenates were spun for 30
min at 20,000 g. After adding 1% sarkosyl, the samples were shaken for
1 h at room temperature and spun at 100,000  g for 1 h at 4°C. The
pellets containing insoluble tau were resuspended in 50 mM Tris-HCl,
pH 7.4, and stored at 4°C until analysis by Western blot.
Coimmunoprecipitation. Retinas were lysed by mechanical disruption
on ice in 1% NP-40, 0.5 M NaCl, 10 mM Na3PO4, 2 mM EDTA, and
protease and phosphatase inhibitors. The lysates were spun at 500 g for
5 min at 4°C to remove unbroken tissue. Equal amount of proteins (250
g) of the supernatants were immunoprecipitated by adding 2.5 g of
the antibody and protein G agarose (Pierce). Protein G agarose beads
alone were used as control for immunoprecipitation. Samples were in-
cubated overnight at 4°C while being constantly shaken. After extensive
washing, the precipitates were eluted from the beads by boiling in sample
buffer for 5 min. Precipitated proteins were separated by 7.5% SDS-
PAGE and transferred to nitrocellulose membranes for Western blot
analysis.
Statistical analysis. Statistical analysis of groups with normal distribu-
tions was performed using a Student’s t test for two groups or ANOVA in
case of multiple comparisons. When the normality test failed, the analysis
was performed using nonparametric tests, such as the Mann–Whitney
rank-sum test or the Kruskal–Wallis one-way ANOVA on ranks followed
by a post hoc test according to Dunn’s or Student–Newman–Keuls meth-
ods. A two-way ANOVA followed by multiple comparisons with the
Holm–Sidak method was performed in some instances. Differences
among groups were considered statistically significant when p  0.05.
Data throughout the text are reported as average values  SEM, except
when otherwise specified.
Results
RGC activity is reduced in P301S mice
To investigate how a mild degree of tauopathy affects retinal
physiology in P301S mice, we used ERG to measure the response
of the retina to patterned light stimuli that specifically elicit RGC
activity (pERG; Porciatti, 2007) or to flickered uniform light
[flash ERG (fERG)] that elicits responses from PRs and the outer
retina (mainly bipolar cells; Porciatti, 2007). For pERG, anesthe-
tized mice were shown squared pattern stimuli alternating in
counter phase at 1 Hz, at saturating contrast and spatial fre-
quency. In WT mice, the typical waveform of pERG consists of a
positive P1 wave (amplitude SD, 5.9 3.1 V; latency SD,
74.9 16.4 ms) and a negative N2 component (amplitude SD,
2.7  1.5 V; latency  SD, 209.2  35.2 ms; Fig. 1A–C). In
transgenic P301S mice, the peak amplitudes of both the P1 and
N2 components were significantly reduced by 39 and 48%, re-
spectively (Fig. 1B), and their peak latency was increased (Fig.
1C). Consistent with a delayed response and increased rise time,
the amplitude of the P1 wave detected at the median latency of
WT (i.e., 72.5 ms) was reduced by 51% in P301S mice (average
SD: WT, 4.3  3.2 V; P301S, 2.1  1.3 V; p  0.01 vs WT,
Mann–Whitney rank-sum test). To determine the impact on vi-
Figure 1. RGC activity is reduced in P301Smice. A, Representation of pERG assessment in themouse. Anesthetizedmice were presented a square pattern of black andwhite stripes reversing at
a rate of 1Hz,with constant luminance,maximal contrast, and spatial frequency (inset). Retinal activitywasmeasured througha corneal electrode.AveragepERGwaveform recorded in5-month-old
P301Smice and age-matchedWTmice are shown.B, C, Box plots of P1 andN2 peak amplitude (B) and latency (C) values in P301S (n 15) andWT (n 16)mice. Average values of individualmice
are overlaid on each plot (gray circles). In each box,median (white line) andmean (dotted gray line) values are indicated. *p 0.05, **p 0.01, Mann–Whitney rank-sum test.D, Representative
visual acuity determination in one WT mouse. The dotted line represents the noise level. The shaded area represents the SD of noise measurements. E, Visual acuity of P301S and WT mice. Bars
representmean SEM. **p0.01, Student’s t test.WT,n5; P301S,n4.F, Representativemouse fERG responseuponexposure to light flicker ofmaximal luminance30 cd s/m 2. Thenegative
response (awave) and positive (bwave) waves represent the response of PRs and bipolar cells, respectively. G, Peak amplitude of a and bwaves in P301S andWTmice. Bars represent the average
amplitude SEM. n 12 per group.
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sual acuity (Fig. 1D), WT and P301S mice were exposed to pat-
tern stimuli with spatial frequencies ranging from 0.05 to 0.7
c/deg. In agreement with steady-state pERG results, retinal acuity
was significantly lower in P301S mice than in WT mice (Fig. 1E).
These findings indicate that despite anatomical preservation of
RGC number (Gasparini et al., 2011), mild levels of tau pathology
are sufficient to trigger significant RGC dysfunction.
To investigate whether tau pathology in RGCs was associated
with general retinal impairment, we evaluated the anatomical
and functional integrity of the outer retina and bipolar cells. Us-
ing sections from the central retina, we examined the integrity of
PRs by counting the number of nuclei in the outer plexiform layer
of WT and P301S retinas. The number of rows of PR nuclei was
similar in WT (9.8 0.8) and P301S (9.3 0.5; p 0.61 vs WT,
Student’s t test) retinas. To examine the functional status of the
outer retina, WT and P301S mice were exposed to uniform flick-
ers of light of increasing luminance generated by a Ganzfeld
dome and the retinal response was recorded through fERG. A
typical fERG waveform includes a and b waves, which mainly
represent the activity of PRs and bipolar cells, respectively (Fig.
1F). In WT mice, the PR response (i.e.,awave) is either undetectable
or very low at luminance ranging from 0.001 to 0.03 cd s/m2 and
increases at luminance	0.03 cd s/m2, reaching amplitudes compa-
rable to those of the b wave at the maximal luminance, i.e., 30 cd
s/m2 (Fig. 1F). To compare fERG responses of WT and P301S reti-
nas, mice were exposed to maximal stimuli (luminance 30 cd s/m2),
representing the most challenging setting, to highlight any subtle
differences between genotypes. In these conditions, the amplitudes
of both a and bwaves were similar in WT and P301S mice (Fig. 1G).
Likewise, the ratio between a and bwaves was not statistically differ-
ent in WT (1.10.2,n12) and P301S mice (1.10.1,n12;p
0.9 vs WT, Mann–Whitney rank-sum test), indicating that the over-
all activity of the outer retina is preserved in transgenic mice.
Overall, these findings indicate that in P301S transgenic mice,
tau pathology in RGCs is associated with a specific impairment of
their activity and reduced retinal acuity, with preserved function
of other retinal neurons, which are devoid of tau pathology.
BDNF secretion in the vitreous is impaired in P301S mice
We have previously demonstrated that in retinal explants cul-
tured from adult P301S transgenic mice, axonal outgrowth is
impaired in response to a mixture of neurotrophic factors, in-
cluding BDNF (Gasparini et al., 2011). BDNF plays a key role in
retinal plasticity and visual acuity refinement during develop-
ment (Landi et al., 2007, 2009; Liu et al., 2007; Schwartz et al.,
2011) and, in cultured neurons, its synthesis and secretion is
regulated by neuronal activity (Hardingham et al., 2002; Matsu-
moto et al., 2008). We therefore investigated whether in P301S
retinas the reduced retinal activity was associated with altered
BDNF metabolism or secretion.
BDNF forms upon cleavage of the precursor pro-BDNF in the
retina (data not shown), is mainly expressed in the RGC and inner
plexiform layers (data not shown; Grishanin et al., 2008), and is
secreted into the vitreous. We found that mRNA levels of BDNF
were unchanged in P301S retinas compared with WT (Fig. 2A).
Likewise, protein levels of both pro-BDNF (Fig. 2B,C) and mature
BDNF (Fig. 2D) were similar in P301S and WT retinas, indicating
that BDNF synthesis is preserved in transgenic mice.
To determine whether there were changes in BDNF secretion,
we measured vitreal levels of the protein. In P301S mice, the
concentration of BDNF in the vitreous was reduced by 72% com-
pared with WT (Fig. 2E), indicating a strong impairment of
BDNF release. One possible explanation for the reduction in vit-
real BDNF levels is impaired RGC activity. To test this hypothe-
sis, we inhibited retinal activity in WT mice through intravitreous
injection with the sodium channel blocker TTX (Miura et al.,
2009) and measured BDNF in the vitreous 2.5 h later. BDNF
levels were significantly reduced in TTX-injected mice (Fig. 2F),
suggesting that impaired RGC activity explains the reduced vit-
real levels of BDNF in P301S mice.
TrkB receptor is upregulated in RGCs of P301S
transgenic mice
To examine how tauopathy affects BDNF signaling in P301S
RGCs, we next analyzed the expression of the BDNF receptor
TrkB, and the related neurotrophin receptors P75NTR and TrkA.
In the retina, TrkB is mainly expressed in RGC and inner plexi-
form layers (Grishanin et al., 2008; data not shown). In P301S
mice, TrkB protein levels were significantly upregulated com-
pared with WT mice (Fig. 3A,B), while P75NTR and TrkA were
unchanged (Fig. 3A,B). To determine whether TrkB upregula-
tion was mediated through an effect on gene expression, we eval-
uated TrkB mRNA levels by quantitative real-time PCR. mRNA
levels were similar in P301S (1.1 0.1) and WT (1.0 0.1; p
0.73, Student’s t test) retinas, indicating unchanged TrkB gene
transcription.
We next asked whether TrkB upregulation could be caused by
impaired retinal activity. To test this hypothesis, we intravitreally
injected WT mice with TTX to inhibit retinal activity and, 2.5 h
later, dissected the retinas and analyzed TrkB levels by Western
blot. TrkB levels were unchanged in TTX-treated retinas (TrkB/
Figure 2. BDNF levels are reduced in the P301S vitreous.A, mRNA expression of BDNF in the
retina of P301S and WT mice. BDNF mRNA levels were analyzed by real-time PCR and normal-
ized to the housekeeping genes actin and GAPDH. Bars represent the average relative expres-
sion SEM.WT, n 7; P301S, n 8.B, C, Pro-BDNF protein levels in the retinas of P301S and
WTmice.B,Western blot analysis of pro-BDNF. Each lane corresponds to retinal lysate fromone
mouse. Tubulin was analyzed as loading control. C, Quantitative analysis of pro-BDNF protein
levels. Values were normalized to tubulin levels. Bars represent the average ratio SEM. WT,
n 6; P301S, n 11. D, E, BDNF levels in the retinas (D) and vitreous (E) fromWT and P301S
mice, determined by ELISA. The bars represent the average BDNF level SEM. **p 0.01,
Mann–Whitney rank-sum test. InD,WT,n10; P301S,n9. InE,n8per group.F, Vitreal
levels of BDNF inWTmice injected intravitreally with TTX or vehicle, determined by ELISA. Data
represent vitreal concentrations (nanograms per milliliter) SEM, n 12 per group. *p
0.05, Mann–Whitney rank-sum test.
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tubulin, average of saline injected retinas: saline, 0.6 0.1; TTX,
0.5 0.1), suggesting that impaired RGC activity per se does not
acutely affect TrkB levels in RGCs.
TrkB receptor is uncoupled from downstream ERK1/2
signaling in the P301S transgenic retina
To investigate whether higher levels of TrkB functionally com-
pensate for lower levels of BDNF ligand, or whether signaling is
impaired, we examined TrkB’s basal activation state and its abil-
ity to activate upon BDNF stimulation. TrkB signals through two
distinct pathways. One pathway is activated by phosphorylation
of TrkB on tyrosine 816 (Y816) and is mediated by phospholipase
C (PLC) and calcium elevation, while the second is activated
by phosphorylation on tyrosine 516 (Y516) and leads to activation
of ERK1 and ERK2 (Minichiello, 2009). To investigate the basal
activity of the PLC-mediated pathway, we first examined the
phosphorylation of TrkB on Y816 (p[Y816]TrkB) and the levels of
PLC phosphorylation on Y783 (p[Y783]PLC), which is indica-
tive of its activation (Choi et al., 2007). There was no significant
difference in the basal levels of p[Y816]TrkB in the retinas of
P301S and WT mice (Fig. 3C,D). Furthermore, the retinal expres-
sion of PLC (Fig. 3C,E) and levels of activated PLC (Fig. 3C,F)
were similar, indicating that this pathway is not significantly al-
tered in P301S mice.
We next investigated TrkB signaling through ERK1/2. We
found that phosphorylation of Y516 on TrkB (p[Y516]TrkB) was
significantly reduced in naive P301S retinas (p[Y516]TrkB/TrkB,
0.6  0.1) compared with WT retinas (1.0  0.01; p  0.01,
Mann–Whitney rank-sum test, n  6 per group), while basal
levels of ERK1/2 were unchanged (ERK1/tubulin: WT, 0.18 
0.05; P301S, 0.13  0.05; p  0.46, Mann–Whitney rank-sum
test, n 7. ERK2/tubulin: WT, 0.82 0.03; P301S, 0.78 0.09;
p 1.0, Mann–Whitney rank-sum test, n 7). To determine the
level to which TrkB activates ERK1/2 signaling upon ligand bind-
ing, we stimulated retinas by intravitreal injections of BDNF or
an equal amount of BSA as a control. To elicit a robust response
of the receptor and highlight any subtle differences between ge-
notypes, we used 2 g of BDNF. This dose effectively rescues the
neurodegenerative phenotype and retinal dysfunction in a mouse
model of glaucoma (Domenici et al., 2014) and is consistent with
doses previously used in the majority of studies on neuroprotec-
tive properties of BDNF in the retina of rodents (Khalin et al.,
2015). Ten minutes after intravitreous injection, mice were killed
and retinas dissected for Western blot analysis of p[Y516]TrkB
and ERK1/2 phosphorylation (Fig. 3G). In BSA-injected P301S
retinas, p[Y516]TrkB was reduced (Fig. 3G,H), while phospho-
ERKs were unchanged compared with WT (Fig. 3G, I, J). In WT
mice, BDNF stimulation increased the phosphorylation of
[Y516]TrkB by
69% (Fig. 3G), and the phosphorylation of ERK1
and ERK2 by 
8-fold and 
4-fold, respectively (Fig. 3G, I, J).
However, in P301S mice, BDNF stimulation did not cause any
significant activation of TrkB signaling or phosphorylation of
ERK1/2. In fact, levels of p[Y516]TrkB and phospho-ERK1/2 were
similar in P301S retinas stimulated with BDNF or BSA (Fig.
Figure 3. TrkB receptor is uncoupled from ERK signaling in the P301S retina. A, Western blot analysis of the TrkB, TrkA, and P75NTR receptors in WT and P301S retinas. Tubulin was analyzed as
loading control. The asterisk indicates the band of truncated TrkB. Each lane corresponds to retinal lysate from one mouse. B, Quantitative analysis of the protein levels of TrkB, P75NTR, and TrkA
receptors in the retinas of WT and P301Smice. Values were normalized to tubulin. Bars represent the average ratio SEM. **p 0.01, Student’s t test. For TrkB: WT, n 12; P301S, n 13; for
p75NTR and TrkA: n 6 per group. C, Western blot analysis of the p[Y816]TrkB, TrkB, phosphorylated PLC (pPLC), and PLC in WT and P301S retinas. Tubulin was analyzed as loading control.
The asterisk indicates the band of truncated TrkB. Each lane corresponds to retinal lysate from onemouse. D, Phosphorylation of TrkB on Y816 in the retinas of WT and P301Smice. p[Y816]TrkB and
TrkB levels were analyzed byWestern blot and normalized on total receptor expression. Bars represent the average ratio SEM. n 7 per group. E, F, Protein levels of total PLC (E) and pPLC
(F ) inWT andP301S retinas. Levels of PLC and pPLCwere analyzed byWestern blot. PLCwas normalized on tubulin. pPLCwas normalized on the expression of the unphosphorylated protein.
Bars represent the average ratio SEM. n 7 per group. G–J, P301S and WT mice were injected intravitreously with 2g of BDNF or BSA; retinas were dissected 10 min later and analyzed by
Western blot as described inMaterials andMethods.G, Western blot analysis of the p[Y516]TrkB, TrkB, pERK1/2, and ERK1/2 inWT and P301S retinas. Tubulin was analyzed as loading control. The
asterisk indicates the band of truncated TrkB. Each lane corresponds to retinal lysate from one mouse. H, Phosphorylation of TrkB on Y516 in retinas of P301S and WT mice in basal and
BDNF-stimulated conditions. Phospho-TrkB was normalized to total TrkB. Box plots of the ratio values are shown. I, J, Phosphorylation of ERK1 (I ) and ERK2 (J ) in retinas of P301S andWTmice in
basal and BDNF-stimulated conditions. Phospho-ERK1/2 values were normalized to total ERK1/2 proteins. Box plots of the ratio values are shown. In H–J, values of individual mice are overlaid on
each plot (gray circles). In each box, median (white line) and mean (dotted gray line) values are indicated. In H–J: *p 0.05, **p 0.01 two-way ANOVA followed by multiple comparison with
the Holm–Sidak method. In H: P301S, n 10; WT, n 14. In I and J: n 10 per group.
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3G,H–J). Overall, these results indicate that TrkB signaling
through ERK1/2 is specifically impaired in P301S retinas and
that the signaling machinery cannot compensate for ligand
deficiency.
Inhibition of TrkB/ERK signaling impairs RGC activity
We next investigated whether defective TrkB signaling per se reduces
RGC activity. To inhibit TrkB in WT mice, we treated mice system-
ically with the TrkB inhibitor ANA12 (Cazorla et al., 2011b). We first
confirmed that systemic administration of ANA12 inhibits TrkB sig-
naling in the retina. Mice were injected intraperitoneally with
ANA12 or vehicle and, 3.5 h later, retinas were challenged by intra-
vitreal BDNF or BSA for a further 30 min. Retinas were dissected and
processed to analyze p[Y516]TrkB. Consistent with previous findings
(Cazorla et al., 2011b), ANA12 selectively inhibited BDNF-
stimulated TrkB receptor activation in the WT retina (Fig. 4A), with-
out affecting NGF-stimulated phosphorylation of TrkA (Fig. 4B).
Using pERG, we therefore examined whether inhibition of TrkB by
ANA12 treatment for 4 h affected RGC activity in WT mice. ANA12
administration significantly decreased by 30% the peak amplitude of
the P1 wave (Fig. 4C). Despite a trend toward increasing P1 peak
latency, ANA12 did not significantly change P1 peak latency (Fig.
4D). To verify the block of TrkB signaling, after ERG recording, we
analyzed phosphorylated ERKs (pERKs) in the retinas of treated
mice. In mice treated with ANA12, pERK levels were significantly
reduced (Fig. 4E), suggesting that TrkB inhibition prevents light-
induced ERK activation. To further explore the role of ERKs in visual
response, we injected the ERK inhibitor PD0325901 or vehicle in the
vitreous of WT mice and analyzed RGC activity by pERG. Vehicle
injection alters neither peak amplitude (5.0  0.9 V) nor peak
latency (88.2 14.1 ms) of P1 compared with noninjected mice (P1
peak amplitude, 5.4 0.4V; p 0.46; P1 peak latency, 91.5 6.1
ms, p  0.54, n  9). In eyes injected with PD0325901, RGC re-
sponse was significantly altered. PD0325901 did not affect P1 peak
latency (Fig. 4G), but significantly reduced the peak amplitude of P1
(Fig. 4F). We also analyzed levels of pERKs by Western blot. Retinal
levels of pERKs were significantly reduced by PD0325901 injection
(Fig. 4H), confirming the inhibition of ERKs.
Together, these results indicate that both TrkB and ERKs are
required for full RGC activity, suggesting that reduced TrkB/ERK
signaling likely contributes to retinal dysfunction in P301S mice.
RGC activity and TrkB expression are preserved in young
P301S mice
To investigate the relationship of retinal activity and TrkB expres-
sion with tau inclusions, we next examined how these vary with
the progression of tauopathy. In P301S retinas, occasional tau
inclusions positively stained by the Congo red analog FSB were
detected as early as 7– 8 weeks of age (Gasparini et al., 2011; Scho¨n
et al., 2012). The number of inclusions increases in a stepwise
manner, reaching steady-state values at 3 months of age (number
of RGCs with FSB-positive tau inclusions/retina: 2.5 months,
10.4  1.8; 3 months, 33.0  1.7; 5 months, 36.7  1.1). To
examine how the progression of tau pathology affects retinal
function, we assessed pERG response in 1-month-old, 3-month-
old, and 5-month-old WT and P301S mice. In P301S mice, the
peak amplitude of both P1 and N2 waves were reduced compared
with WT only at 5 months of age, while they were preserved at
younger ages (Fig. 5A,B). Similarly, the latency of both P1 and
N2 was reduced in 5-month-old P301S mice (Fig. 1), while it was
unchanged at age 1 month (average  SD: P1: WT, 92.8 12.4
ms; P301S, 104.8 10.9 ms; p 0.09, Student’s t test. N2: WT,
250.8  14.3 ms; P301S, 250.4  24.8 ms; p  0.97, Student’s t
test) and 3 months (average SD: P1: WT, 82.2 6.9 ms; P301S,
92.5 16.8 ms; p 0.15, Student’s t test. N2: WT, 242.9 17.1
ms; P301S, 241.4 13.9 ms; p 0.87, Student’s t test). We next
examined TrkB levels in relation to tauopathy progression. Similar
to retinal function, changes in TrkB were detected only in 5-month-
Figure 4. Inhibition of TrkB and ERK reduces RGC activity. A, B, WT mice were injected
intraperitoneally with 1mg/kg ANA12 (ANA) or vehicle (VEH). BDNF, NGF, or BSAwere injected
in the vitreous 3.5 h later. After 30 min, retinas were dissected and p[Y516]TrkB or p[Y490]TrkA
levelswere analyzedbyWesternblot (A) or ELISA (B) as described inMaterials andMethods and
normalized to total TrkB or TrkA expression. Bars represent the average ratio SEM. *p
0.05, **p 0.01, two-way ANOVA followed by Holm–Sidak multiple-comparison test. C, D,
RGC activity of WT mice after inhibition of TrkB with ANA12. WT mice were injected intraperi-
toneallywith 1mg/kg ANA12 or vehicle and 4 h laterwere anesthetized and subjected to pERG.
Box plots of peak amplitude (C) or latency (D) of P1wave inWTmice treatedwith VEH (n 14)
or ANA12 (n 16) are shown. Average values of individualmice are overlaid on each plot (gray
circles). In each box, median (white line) and mean (dotted gray line) values are indicated.
**p 0.01, Mann–Whitney rank-sum test. E, pERK levels after ANA12 injection. pERKs were
analyzed by Western blot and normalized to total ERK expression. Bars represent the average
ratio SEM. *p 0.05, Student’s t test. F, G, RGC activity of WTmice after inhibition of ERKs.
WT mice were injected with 20 nM PD0325901 (PD) or VEH in the vitreous and 1 h later were
anesthetized and subjected to pERG. F, G, Box plots of peak amplitude (F ) or latency (G) of P1
wave in WT mice treated with VEH or PD are shown. Average values of individual mice are
overlaid oneachplot (gray circles). In eachbox,median (white line) andmean (dottedgray line)
values are indicated. **p 0.01, Student’s t test. n 9 per group. H, pERK levels after PD
injection. pERKs were analyzed by Western blot and normalized to total ERK expression. Bars
represent the average ratio SEM. *p 0.05, Student’s t test.
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old transgenic mice: TrkB was upregulated in 5-month-old P301S
mice and was normal at 1 month and 3 months of age (Fig. 5C,D).
These results indicate that retinal dysfunction and changes in TrkB
levels coincide in time and occur after a steady state of tau inclusions
has already developed.
Tauopathy levels drive TrkB upregulation
Recent findings indicate that tau pathology spreads in a hierar-
chical manner among anatomically connected areas (Kfoury et
al., 2012; de Calignon et al., 2012; Ahmed et al., 2014; Hyman,
2014). Here, we took advantage of this self-propagating behavior
to accelerate retinal tauopathy in young P301S transgenic mice
and investigate how tauopathy specifically relates to the changes
of retinal activity and TrkB levels. To enhance tau pathology, we
injected brain extract from 5-month-old P301S mice (P301SBE)
in the superior colliculus (SC) of P301S mice at 1.5 months of age
(Fig. 6A,B). Six weeks later, we examined tau pathology in the
retina, ON, and brain of injected and not-injected (NI) mice.
Changes in the content of total tau and phospho-tau were de-
tected only in anatomically connected areas. Specifically, in
P301SBE-injected transgenic mice, levels of total tau protein were
significantly increased in the ON (Fig. 6F,G). In the SC and
retina, although there was a trend toward an increase (38 and
50%, respectively), the difference in total tau was not statisti-
cally significant (Figs. 6C,D, 7A,B). In contrast, tau phosphory-
lation was significantly enhanced in all three connected areas in
P301SBE-injected transgenic mice. In fact, levels of AT8-positive
phospho-tau were increased by 	50-fold in the SC (Fig. 6C,E),
45-fold in the ON (Fig. 6F,H), and sixfold in the retina (Fig. 7C).
Immunohistochemistry also showed increased phospho-tau in
the SC and visual cortex of mice injected with P301SBE (Fig.
6 J,K). Levels of tau and phospho-tau did not vary in the cerebel-
lum (Fig. 6I), which is not anatomically connected with the SC.
These results indicate that 6 weeks after P301SBE injection in the
SC, tau pathology worsens in anatomically connected areas of the
visual system of 3-month-old P301S mice. This method can
therefore be used to experimentally manipulate levels of tau pa-
thology to study tauopathy-dependent molecular changes.
We next examined the retinal expression of TrkB as a function
of tau content. In transgenic mice injected with P301SBE, retinal
levels of TrkB were increased by 50% (Fig. 7A,D). To investigate
the relationship between levels of TrkB and tau, we performed
regression analyses. We found that retinal levels of TrkB signifi-
cantly varied in direct proportion with those of total tau (Fig. 7E)
and of AT8-positive phospho-tau (Fig. 7F), indicating that the
TrkB upregulation is likely dependent on tau levels.
To test whether increasing the levels of WT murine tau is
sufficient to enhance tauopathy and TrkB expression in the ret-
ina, we injected 1.5-month-old P301S transgenic mice with brain
extract from WT mice (WTBE). Six weeks later, levels of total tau
were unchanged in SC (Fig. 6C,D), ON (Fig. 6F,G), and retina
(Fig. 7A,B) of WTBE-injected transgenic mice. While levels of
total tau and phospho-tau were not significantly changed in the
SC or ON (Fig. 6C–H), there was a significant increase in
phospho-tau in the retina of WTBE-injected transgenic mice (Fig.
7C), similar to that achieved in the retina of sham-injected trans-
genic mice (AT8/tau ratio: sham, 11.5 1.8; WTBE, 11.2 2.0).
However, levels of TrkB in the retina were not significantly af-
fected in WTBE-injected (Fig. 7D) and sham-injected (TrkB/ac-
tin: NI, 0.9  0.1; sham, 0.8  0.1) transgenic mice compared
with NI, suggesting that altered phosphorylation of murine tau
alone does not affect TrkB levels.
Tauopathy levels drive RGC activity dysfunction
To examine the effects of accelerating tau pathology on RGC func-
tion, we analyzed pERG response in transgenic mice injected with
either WTBE or P301SBE and in NI P301S transgenic mice. We found
that the pERG response was significantly slower in P301SBE-injected
transgenic mice compared with WTBE-injected or NI transgenic
mice (Fig. 7G,H) and both P1 (Fig. 7G,H) and N2 (latency SD:
WTBE, 213.016.0 ms; P301SBE, 290.346.2 ms;p0.05, Mann–
Whitney rank-sum test) waves peaked at increased latency. Consis-
tently, the mean P1 amplitude of the pERG response measured at the
median latency of NI (i.e., 93.5 ms) was significantly reduced in
P301SBE-injected transgenic mice compared with both NI and
WTBE-injected mice (Fig. 7J). Despite a trend toward reduction, the
peak amplitude of P1 was not significantly different from those of NI
and WTBE-injected mice (Fig. 7I). These results suggest that levels of
tau pathology exceeding a certain threshold are required to signifi-
cantly alter RGC activity in the P301S mouse, mainly affecting the
response rising time.
TrkB–fyn interaction is altered in the P301S retina
We next examined the mechanisms by which tau pathology pro-
motes TrkB upregulation and impairs signaling. Through binding
microtubules, tau regulates both anterograde and retrograde axonal
Figure 5. RGC activity and TrkB expression are preserved in the early stages of tauopathy. RGC activity and TrkB expressionwere analyzed in P301S andWTmice at preinclusion (1month of age),
onset (3months of age), and full-blown stages (5months of age) of retinal tauopathy as described inMaterials andMethods.A,B, Peak amplitude of P1 (A) and N2 (B) waves inWT and P301Smice
as detected by pERG. Bars represent the average amplitude SEM. *p 0.05, Student’s t test. C, Western blot analysis of the TrkB in retinas of WT and P301S mice at 1, 3, and 5 months of age.
Tubulin was analyzed as loading control. The asterisk indicates the band of truncated TrkB. Each lane corresponds to retinal lysate from one mouse. D, TrkB protein expression in the retina of
1-month-old, 3-month-old, and 5-month-old P301S andWTmice. TrkB was analyzed byWestern blot and normalized to tubulin. Bars represent the average ratio SEM. **p 0.01, Student’s t
test. In all panels, numbers in brackets indicate the number of animals used per group.
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transport in vitro (Dixit et al., 2008). It has been also shown that the
N terminus of tau binds to dynactin p150, a subunit of the dynein
retrograde motor complex (Magnani et al., 2007). This motor pro-
tein is involved in the trafficking of neurotrophin receptors, includ-
ing TrkB (Deinhardt et al., 2006), and accumulates at tau-rich sites in
axons of retinal explants from adult P301S mice (Magnani et al.,
2007). We therefore hypothesized that the tau-dependent uncou-
pling of TrkB from its downstream signaling pathway could be due
to receptor mislocalization.
To test this hypothesis, we first performed immunofluores-
cence analysis of TrkB and phospho-tau on retinal sections from
5-month-old WT and P301S mice. In P301S retinas, phospho-
tau immunoreactivity is detected in all RGCs, but the signal in-
tensity varies among cells: the brightest signal is indeed detected
in the subset of RGCs that bears filamentous inclusions of
phospho-tau with -sheet secondary structure (Gasparini et al.,
2011). In WT retinas, TrkB immunoreactivity was evenly distrib-
uted in the inner plexiform layer, where RGC dendrites are lo-
Figure 6. Intracollicular injection of P301S brain extract increases tau pathology in the SC and ON of 3-month-old P301Smice.WTBE or P301SBE was injected in the SC (2.92mmbehind bregma)
of P301S mice at 1.5 months of age and levels of tau and phospho-tau in the SC, ON, cerebellum, and visual cortex were analyzed 6 weeks later. Red lines indicate injection sites. A, Western blot
analysis of tau andphospho-tau protein in brain extracts from5-month-oldWT (WTBE) andP301S (P301SBE)mice. Phospho-tauwas analyzed using theAT8,MC1, andPHF-1monoclonal antibodies.
Human tau and total tauwere detected using the HT7 and Tau-5monoclonal antibodies, respectively. Actinwas analyzed as loading control.B, Schematic representation of the injection sites.WTBE
or P301SBEwere injected in the SC (2.92mmbehindbregma) of 1.5-month-old P301Smice. dLGN,Dorsolateral geniculate nucleus; PT, pretectum; PPT, posterior pretectal nucleus; V1, primary visual
cortex. C–I, Tau levels in the SC (C,D, and E), ON (F,G, andH ), and cerebellum (I ) of 3-month-old P301Smice injected 6weeks earlier withWTBE, with P301SBE, or not injected (NI). C, F, I, Western
blot analysis of total tau (Tau-5) and phospho-tau (AT8) in the SC (C), ON (F ), and cerebellum (I ). In F, MemCode staining shows equal loading. D, E, Quantitative analysis of total tau (D) and
phospho-tau (E) in theSC. *p0.05, Kruskal–Wallis one-wayANOVAon ranks followedbypairwisemultiple-comparisonprocedureaccording toDunn’smethod.G,H, Quantitative analysesof total
tau (G) and phospho-tau (H ) in the ON. *p 0.05, Kruskal–Wallis one-way ANOVA on ranks followed by pairwisemultiple-comparison procedure according to Dunn’smethod. J,K, Representative
fluorescence images of AT8 immunoreactivity in the V1 primary visual cortex (J ) and SC (K ) of 3-month-old P301Smice injected intra-SC withWTBE or P301SBE. The images represent phospho-tau
immunoreactivity in coronal sections at 3.60 mm behind bregma. Scale bars, 25m. In all graphs, WTBE, n 10; P301SBE, n 16; NI, n 12.
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cated, in the RGC layer, which contain RGC cell bodies, and in
the nerve fiber layer that is formed by RGC axons (Fig. 8A).
Consistent with biochemical findings, TrkB immunoreactivity
was more intense in RGCs of P301S than those of WT mice.
Specifically, in P301S retinas, the TrkB signal was enhanced in the
RGC soma, where it colocalized with phospho-tau aggregates
(Fig. 8Bb). Further, in RGCs bearing the highest amounts of
phospho-tau, TrkB accumulated both in soma and dystrophic
dendrites (Fig. 8Bb). To investigate whether TrkB accumulates
in tau inclusions, we isolated insoluble tau filaments from the
brains and retinas of 5-month-old WT and P301S mice by sarko-
syl extraction. Similarly to transgenic retinas, TrkB levels were
increased in total lysates of P301S brains (Fig. 8C,D). In the
sarkosyl-insoluble fraction, TrkB was present in similar amounts
in WT and P301S transgenic brains (Fig. 8C,D) or retinas (data
not shown), arguing against cosegregation of the receptor with
filamentous tau aggregates.
TrkB localization and signaling cascade depends on the inter-
action with the SH2 domain of fyn (Iwasaki et al., 1998; Pereira
and Chao, 2007; Zonta and Minichiello, 2013), which also binds
phosphorylated and mutant tau (Bhaskar et al., 2005; Usardi et
al., 2011). We therefore investigated whether tau–fyn interaction
was altered in P301S retinas. In agreement with previous findings
(Lee et al., 2004; Ittner et al., 2010), tau coimmunoprecipitates
with fyn in both WT and P301S retinas. The total levels of fyn
were similar in total retinal lysates of both WT and P301S mice
(Fig. 8E). However, the amount of tau associated with fyn was
greater in P301S than in WT retinas (Fig. 8F). Consistent with an
Figure 7. Increased levels of tau induces upregulation of TrkB in the retina. WTBE or P301SBE were injected in the SC (2.92 mm behind bregma) of P301S mice at 1.5 months of age and
retinas were analyzed 6 weeks later. A, Western blot analysis of TrkB, tau, and phospho-tau protein in retinas of 3-month-old mice injected with WTBE, with P301SBE, or not injected (NI).
Total tau and phospho-tau were detected using the Tau-5 and AT8 monoclonal antibodies, respectively. Actin was analyzed as a loading control. B, C, Quantitative analysis of total tau
(B) and phospho-tau (C, pTau) in the retinas of 3-month-old P301S mice injected with WTBE, with P301SBE, or NI. Values were normalized to actin (B) or total tau (C). Data are expressed
as a percentage of NI and bars represent the average SEM. *p 0.05, Kruskal–Wallis one-way ANOVA on ranks followed by the pairwise multiple-comparison procedure according
to Dunn’s method. D, Quantitative analysis of TrkB in the retinas of 3-month-old P301S mice injected with WTBE, with P301SBE, or NI. E, F, Regression analysis of levels of TrkB and total
tau (E; R 2 0.64; adjusted R 2 0.62; p 0.01) and TrkB and phospho-tau detected by AT8 antibody (F; R 2 0.73; adjusted R 2 0.71; p 0.01) in retinas from mice injected with
P301SBE. In B–F: WTBE, n 10; P301SBE, n 16; NI, n 12. G, pERG response in transgenic mice injected with WTBE, with P301SBE, or NI. Curves represent the respective average
response SD.H, P1 peak latency. I, P1 peak amplitude. J, Response amplitudemeasured at themedian P1 peak latency of NI mice. Graphs inH–J represent average SD. In G–J, WTBE,
n 7; P301SBE, n 9; NI, n 8. *p 0.05, **p 0.01, Kruskal–Wallis ANOVA on ranks followed by pairwise Student–Newman–Keuls multiple-comparison method.
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increased interaction of the two proteins, we found that in P301S
retinas, tau was phosphorylated on tyrosine Y18 (pY18-tau; Fig.
8G,H), a residue phosphorylated by fyn upon binding (Lee et al.,
2004). Fyn localization was also altered in transgenic retinas.
While in WT retinas fyn mainly localized in RGC axons (Fig. 8I),
in P301S retinas fyn also localized in RGC soma and partially
colocalized with pY18-tau immunoreactivity (Fig. 8Jj,Jj).
Overall, these results indicate that in P301S retinas, tau pa-
thology is associated with TrkB accumulation in RGC soma and
dystrophic dendrites, enhanced tau–fyn interaction, and fyn-
mediated tau phosphorylation.
Discussion
Our findings demonstrate that in the retina of 5-month-old P301S
mice, functional changes in neuronal activity are accompanied and
possibly mediated by tau-induced BDNF signaling impairment. The
activity of RGCs and retinal acuity are significantly reduced in P301S
mice, while the overall function of the outer retina is preserved.
Moreover, in P301S mice, the activity-dependent secretion of BDNF
in the vitreous is significantly decreased, likely due to diminished
RGC activity. In P301S retinas, despite being selectively upregulated,
TrkB receptors are uncoupled from their downstream signaling
through ERK1/2. Finally, we show that impairment of both retinal
Figure 8. TrkB–fyn interaction is altered in P301S retina. A, B, Representative maximal projections of z-stack confocal images of WT (A) and P301S (B) retinas immunostained with antibodies
against TrkB (A, B; green), human tau (A, Bb), and phospho-tau (AT8; Bb, red). Nuclei were counterstained with Hoechst-33342 (blue). Scale bars, 25m. Arrows and arrowheads indicate RGC
soma and axons, respectively. Open triangles indicate dystrophic RGC dendrites containing phospho-tau aggregates. Bb, Human tau and TrkB colocalization in the soma of P301S RGCs. Bb,
Accumulation of TrkB in a typical P301S RGC containing mature filamentous aggregates of phospho-tau. C, Western blot analysis of TrkB and phospho-tau in the total brain lysate (BL) and
sarkosyl-insoluble (SI) fraction of brain fromWT and P301Smice at 5months of age. Phospho-tau was detected using the PHF-1monoclonal antibody. The asterisk indicates the band of truncated
TrkB. D, Quantitative analysis of TrkB in total BL and SI fraction of WT and P301S brain. Levels of TrkB were analyzed byWestern blot (C). For BLs, TrkB levels are normalized over actin (P301S, n
6; WT, n 7). For the SI fraction, densitometric values are normalized over levels in WT and bars represent average SEM. P301S, n 12; WT, n 12. A.U., Arbitrary units. E, Western blot and
quantitative analyses of fyn in total retina lysate of WT and P301S mice at 5 months of age. Fyn levels were normalized over tubulin. n 12 per group. F, Coimmunoprecipitation of tau with fyn.
Lysates (input)were immunoprecipitated (IP) using anti-fyn antibody or incubatedwith protein G agarose (PAG) beads alone as control. Sampleswere analyzed byWestern blot for fyn and tau. Two
different exposures of the same Western blot for tau are shown. Densitometry of fyn and tau Western blot from two independent coimmunoprecipitations is shown in the graph. G, Western blot
analysis of pY18-tau, total tau, and actin. Total tau was detected using the Tau-5 monoclonal antibody. H, Quantitative analysis of pY18-tau in the retinas of 5-month-old P301S mice. pY18-tau
values were normalized to total tau. Bars represent the average ratio SEM. **p 0.01, Mann–Whitney rank-sum test. WT, n 11; P301S, n 10. I, J, Representative maximal projections of
z-stack confocal images of WT (I ) and P301S (J ) retinas immunostained with antibodies against pY18-tau (red) and fyn (green). Nuclei are counterstained with DAPI (blue). Scale bars, 25m. Jj,
pY18-tau and fyn colocalization in P301S RGCs. Jj, Typical degenerating P301S RGC filled up with filamentous aggregates of phospho-tau. Arrows and arrowheads indicate RGC soma and axons,
respectively. Open triangles indicate pY18-tau/fyn colocalization in dystrophic RGC dendrites. In A, B, I, and J: NFL, Nerve fiber layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer
plexiform layer; ONL, outer nuclear layer.
2096 • J. Neurosci., February 17, 2016 • 36(7):2086–2100 Mazzaro, Barini et al. • Tau-Driven Retinal Dysfunction
function and TrkB upregulation stem from tau pathology and that
tau-dependent TrkB signaling deficit possibly mediates tau-induced
neuronal dysfunction.
At 5 months of age, P301S tau transgenic mice accumulate
hyperphosphorylated tau and develop tau filamentous inclusions
in a small subset of RGCs. These changes neither alter the overall
anatomy of the retina—inner or outer—nor induce loss of RGCs
(Gasparini et al., 2011), recapitulating pathological alterations of
early-stage tauopathy. Here, we find that this mild pathological
phenotype is sufficient to impair retinal activity. Indeed, consis-
tent with the anatomical distribution of retinal tau pathology in
the P301S mouse, the activity of RGCs is selectively reduced,
while the outer retina is fully functional. This demonstrates that
PR function and synaptic transmission to bipolar cells are not
compromised in transgenic mice and the reduced pERG response
is not a secondary effect due to visual signaling loss in the outer
retina.
The impaired RGC activity seems directly related to reaching a
certain threshold of tau pathology and consequent TrkB dysfunc-
tion in RGCs. In P301S mice, retinal activity is normal at 1 and 3
months of age and declines at 5 months. Similarly, TrkB levels are
upregulated only at 5 months of age. Accelerating tau pathology
by injection of P301SBE, but not WTBE, in the SC of 1.5-month-
old transgenic mice significantly impairs retinal activity at 3
months of age, slowing RGC response to pattern light stimuli.
Again, retinal functional changes induced by P301SBE are accom-
panied by upregulation of TrkB. Thus, in P301S mice, tau-
induced changes of TrkB and retinal function are concurrent,
suggesting a tight link between defective TrkB signaling and RGC
dysfunction. This view is also supported by results obtained using
the TrkB inhibitor ANA12. In WT mice, ANA12 significantly
reduces RGC response to pattern light stimuli, reproducing to
some extent the retinal dysfunction of P301S mice, and suggest-
ing that TrkB signaling contributes to mouse visual response.
However, despite previous (Cazorla et al., 2011b) and current
results indicating that ANA12 is selective for TrkB, we cannot
exclude the possibility that some ANA12 actions may be medi-
ated by non-Trk-mediated mechanisms because an extensive re-
ceptor interaction screening for ANA12 is still missing.
Compelling evidence gathered in the past two decades demon-
strates that BDNF/TrkB signaling acts as modulator of neuronal
activity and synaptic plasticity in the brain (Park and Poo, 2013)
through presynaptic and postsynaptic molecular changes, including
enhanced neurotransmitter release, expression and activity of neu-
rotransmitter receptors, modulation of ion channels, and, in the
long term, transcriptional effects and structural remodeling of ax-
ons, dendrites, and dendritic spines (Lai et al., 2012; Mariga et al.,
2015). Consistently, our results indicate that TrkB contributes to the
maintenance of physiological retinal activity and suggest that re-
duced TrkB signaling impairs the visual response in the mouse, likely
through an ERK-mediated mechanism.
There is evidence that ERKs, in addition to controlling prolif-
eration and differentiation during development, play a key role in
modulating synaptic plasticity in mature neurons (Thomas and
Huganir, 2004). For example, in the visual system, ERK activa-
tion is required for visual cortical plasticity (Di Cristo et al.,
2001), experience-dependent plasticity, and visual recognition
memory (Boggio et al., 2007; Silingardi et al., 2011). Further,
ERKs regulate several synaptic targets in the adult brain (Thomas
and Huganir, 2004), including NMDA and AMPA receptors that
have been demonstrated to be also altered by soluble species and
phosphorylated forms of tau (Hoover et al., 2010; Ittner et al.,
2010). ERKs also mediate several of the neuronal and synaptic
mechanisms of BDNF/TrkB signaling, including enhancement of
neurotransmitter release (Jovanovic et al., 2000), modulation of
Nav and VGCC ion channels (Lesser and Lo, 1995; Woodall et al.,
2008), gene expression (Gaiddon et al., 1996), and structural syn-
aptic plasticity (Alonso et al., 2004; Takei et al., 2004). Within this
context, we now report that ERKs are also required for the phys-
iological response of mouse RGCs. In WT mice, reducing ERK
activation by TrkB inhibition with ANA12 or blocking ERKs by
the specific ERK inhibitor PD0325901 significantly decreases
light-induced RGC activity. Further, in the P301S mouse, defec-
tive ERK signaling is associated with impaired visual response.
These results indicate that ERK signaling is required for proper
visual response in the mouse. Future investigation is warranted to
dissect the molecular, transcriptional, or structural mechanisms
affected in the early stage of tauopathy and their link with im-
paired neurotrophin signaling through ERKs.
Neuropathological studies in human brain samples indicate
that BDNF signaling is altered in AD and non-AD tauopathies,
both at the ligand and receptor levels. BDNF mRNA and protein
levels are decreased in some tauopathies, including Pick’s disease,
corticobasal degeneration (Belrose et al., 2014), and AD (Ferrer et
al., 1999). In the AD brain, TrkB receptors’ immunoreactivity is
also significantly altered in tangle-bearing neurons (Ferrer et al.,
1999). Within this context, our work has yielded key insights into
the early effects of tauopathy on this signaling pathway in relation
to neuronal function. We show that in P301S mice, despite nor-
mal retinal expression and synthesis, vitreal levels of BDNF are
strongly reduced. This finding apparently diverges from previous
work showing that BDNF is not downregulated in the hippocam-
pus of the THY-Tau22 transgenic mouse (Burnouf et al., 2012).
Technical and experimental design differences among various
studies may account for the discrepancy. First, by taking advan-
tage of the natural compartmentalization of the retina, our study,
unlike other studies (Burnouf et al., 2012), distinguishes between
different pools of BDNF, i.e., retinal versus secreted, which re-
veals a selective reduction of secreted BDNF. Further, different
stages of tauopathy or the presence of multiple mutations in tau
(Schindowski et al., 2006) may affect BDNF expression differ-
ently in the brain of the THY-Tau22 transgenic model.
We also show that the reduction of vitreal BDNF likely stems
from impaired RGC activity in P301S retina. Accordingly, we
find that in WT mice, inhibiting retinal activity by TTX signifi-
cantly reduces BDNF levels in the vitreous, reproducing the
transgenic phenotype. This confirms and extends findings in cul-
tured neurons, which have demonstrated that BDNF secretion
depends on neuronal activity (Matsumoto et al., 2008); in the
retina in vivo, the secretion of BDNF is also modulated by RGC
activity.
Further, we gain some insight on the mechanisms by which
initial tauopathy disrupts BDNF signaling at the receptor level. In
5-month-old P301S tau mice, despite being upregulated, retinal
TrkB receptors fail to signal through the ERK pathways. In P301S
retinas, TrkB receptors accumulate in RGC soma and dystrophic
dendrites. TrkB signaling depends on the interaction of the re-
ceptor with the tyrosine kinase fyn (Iwasaki et al., 1998; Pereira
and Chao, 2007), which also interacts with tau (Lee et al., 2004;
Pooler et al., 2012). The tau–fyn interaction is enhanced when tau
is phosphorylated (Usardi et al., 2011) or bears specific muta-
tions, including the P301L mutation (Bhaskar et al., 2005). Even
though the expression of fyn in WT retinas is similar to that in
P301S retinas, the tau–fyn interaction is increased in transgenic
retinas and fyn partially colocalizes with phospho-tau. This sug-
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gests that excessive tau–fyn binding may prevent the stabilization
of other protein complexes, including TrkB, and induce abnor-
mal tau phosphorylation. Consistently, in P301S transgenic reti-
nas, there is robust phosphorylation of tau on Y18, which is
typically phosphorylated by fyn and accumulates in paired helical
filaments extracted from the human AD brain (Lee et al., 2004).
In conclusion, our results support a model in which early tau
pathology impairs TrkB signaling through ERKs. This would re-
sult in neuronal dysfunction and reduction of activity-dependent
BDNF secretion, starting a deleterious vicious cycle that possibly
leads to neurodegeneration at later stages. These findings are
clinically relevant from diagnostic and therapeutic perspectives.
From a diagnostic viewpoint, the results suggest that retinal ex-
amination may be useful for diagnosing AD, even though the eye
is not the main area targeted by AD pathology. In fact, the retinas
of some, though not all (Ho et al., 2014), AD patients develop
amyloid plaques (Koronyo-Hamaoui et al., 2011; Tsai et al.,
2014), inclusions of phosphorylated tau (Scho¨n et al., 2012),
RGC degeneration (Blanks et al., 1989, 1991, 1996a,b), and reti-
nal dysfunction (Parisi, 2003; Iseri et al., 2006). Interestingly, in a
subset of cases, AD manifests with early visual symptoms (Lee
and Martin, 2004). Such symptoms are believed to be of cortical
origin and posterior cortical atrophy has been proposed as a new
clinical entity (Crutch et al., 2012). However, a systematic analy-
sis of AD patients with visual symptoms and their retinal function
is still lacking. Further investigation should explore the potential
use of noninvasive, clinically available electrophysiological tech-
niques, such as ERG, to detect early pathophysiological changes
in this subset of AD cases.
From the therapeutic perspective, clinical trials using BDNF
have been conducted in neurodegenerative disorders, such as
amyotrophic lateral sclerosis and diabetic neuropathy, with in-
conclusive results (Ochs et al., 2000; Thoenen and Sendtner,
2002). While BDNF bioavailability might have been an issue in
the failure of such trials, other possible reasons for failure include
pharmacodynamic aspects, such as possible lack of target engage-
ment. Rather, our data suggest that pathological dysfunction of
the TrkB/BDNF pathway occurs at an early stage of tauopathy,
preventing activation of the pathway by exogenous BDNF and
leading to neuronal dysfunction. This raises concerns about the
benefit of BDNF/TrkB-targeting drugs (e.g., 7, 8-dihydroxyfla-
vone; Marongiu et al., 2013) for tau-induced neurodegeneration.
Overall, our results underscore the need for a better understand-
ing of the molecular changes associated with early tauopathy
stages to support informed therapeutic decisions.
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